Castration Resistant Prostate Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for castration resistant prostate cancer. 28 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
28
Active US patents
67/100
Avg vulnerability
$2.6B
Annual revenue covered

Originators in Castration Resistant Prostate Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson 28 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating castration resistant prostate cancer. Each bar = one year. Y-axis scaled to peak year (10 patents).

6
27
2
30
10
33
2
35
2
38
4
40
2
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Erleada
apalutamide
 Johnson & Johnson 28 67 $2.6B 2027-03-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8802689 Erleada method of use 88 2027-03-27
8802689 Erleada method of use 80 2027-03-27
8445507 Erleada method of use 76 2030-09-15
RE50642 Erleada method of use 75 2033-09-23
RE50642 Erleada method of use 75 2033-09-23
11963952 Erleada method of use 75 2040-01-30
12303497 Erleada method of use 75 2040-01-30
12303497 Erleada method of use 75 2040-01-30
11963952 Erleada method of use 75 2040-01-30
11723898 Erleada method of use 75 2041-01-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9388159 Erleada composition of matter 22 2027-03-27
9388159 Erleada composition of matter 30 2027-03-27
12303493 Erleada formulation 55 2035-12-03
12303493 Erleada formulation 55 2035-12-03
9987261 Erleada formulation 60 2027-03-27
10702508 Erleada method of use 62 2038-04-30
9884054 Erleada method of use 62 2033-09-23
10849888 Erleada method of use 62 2033-09-23
9481663 Erleada method of use 62 2033-06-04
8445507 Erleada method of use 68 2030-09-15

Related